For example, the simultaneous suppression of tumor cell survival by targeting factors such as Bcl-2 or TGF-ß using RNAi approaches while simultaneously increasing the immunogenicity of tumor cells by activating RIG-I with 5’-ppp RNAs can decrease tumor viability. The gene discussed is BCL2; the disease is neoplasm.